BridgeBio Pharma (NASDAQ: BBIO) CAO sells 2,000 shares in 10b5-1 trading plan

Q: What insider transaction did BBIO executive Maricel Apuli report?

Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma (BBIO) , reported selling 2,000 shares of Common Stock on July 30, 2026, at $80.06 per share in an open-market transaction under a pre-arranged Rule 10b5-1 sales plan.

Q: At what price did Maricel Apuli sell BBIO shares?

Apuli sold 2,000 BBIO shares at a price of $80.06 per share . The transaction occurred on July 30, 2026, and is classified as a sale in an open market or private transaction under SEC transaction code S.

Q: Was the BBIO insider sale by Maricel Apuli made under a Rule 10b5-1 plan?

Yes. The sale of 2,000 BBIO shares by Maricel Apuli was effected pursuant to a Rule 10b5-1 sales plan adopted on September 8, 2025 , indicating the transaction followed a pre-established trading arrangement.

Q: What is Maricel Apuli’s role at BridgeBio Pharma (BBIO)?

Maricel Apuli serves as the Chief Accounting Officer of BridgeBio Pharma (BBIO). The reported Form 4 transaction reflects her personal direct holdings in the company’s Common Stock and changes due to the July 30, 2026 open-market sale.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma Chief Accounting Officer Maricel Apuli sold 2,000 shares of Common Stock on July 30, 2026 at $80.06 per share in an open-market transaction under a Rule 10b5-1 sales plan adopted on September 8, 2025, and now directly holds 127,401 shares.

Insider Trade Summary 10b5-1

Net Seller: 2,000 shares

Net Sell 1 txn

Insider Apuli Maricel

Role Chief Accounting Officer

Sold 2,000 shs ($160K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^F1	2,000	$80.06	$160K

Holdings After Transaction: Common Stock — 127,401 shares (Direct)

Footnotes (1)

F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.

Key Figures

Shares sold: 2,000 shares Sale price per share: $80.06 Shares owned after sale: 127,401 shares +2 more

5 metrics

Shares sold 2,000 shares Common Stock sale on 2026-07-30 by Chief Accounting Officer

Sale price per share $80.06 Price per share for Common Stock sold on 2026-07-30

Shares owned after sale 127,401 shares Direct ownership of BridgeBio Pharma Common Stock following the transaction

Transaction date 2026-07-30 Date of open-market sale of Common Stock by Maricel Apuli

10b5-1 plan adoption date September 8, 2025 Adoption date of Rule 10b5-1 sales plan governing the reported sale

Key Terms

Rule 10b5-1 sales plan, Sale in open market or private transaction, Common Stock

3 terms

Rule 10b5-1 sales plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 sales plan"

Sale in open market or private transaction market

"transaction code description: Sale in open market or private transaction"

Common Stock financial

"security title: Common Stock sold by the reporting person"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 04:21 PM Accepted by SEC EDGAR 08/03/2026 - 04:20 PM

FAQ

What insider transaction did BBIO executive Maricel Apuli report?

Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma (BBIO), reported selling 2,000 shares of Common Stock on July 30, 2026, at $80.06 per share in an open-market transaction under a pre-arranged Rule 10b5-1 sales plan.

At what price did Maricel Apuli sell BBIO shares?

Apuli sold 2,000 BBIO shares at a price of $80.06 per share. The transaction occurred on July 30, 2026, and is classified as a sale in an open market or private transaction under SEC transaction code S.

How many BBIO shares does Maricel Apuli hold after the reported sale?

Following the July 30, 2026 sale, Maricel Apuli directly holds 127,401 shares of BridgeBio Pharma (BBIO) Common Stock. This post-transaction ownership reflects the position after disposing of 2,000 shares in the open-market sale.

Was the BBIO insider sale by Maricel Apuli made under a Rule 10b5-1 plan?

Yes. The sale of 2,000 BBIO shares by Maricel Apuli was effected pursuant to a Rule 10b5-1 sales plan adopted on September 8, 2025, indicating the transaction followed a pre-established trading arrangement.

What is Maricel Apuli’s role at BridgeBio Pharma (BBIO)?

Maricel Apuli serves as the Chief Accounting Officer of BridgeBio Pharma (BBIO). The reported Form 4 transaction reflects her personal direct holdings in the company’s Common Stock and changes due to the July 30, 2026 open-market sale.

How many BBIO shares were sold in the latest insider transaction?

The latest insider transaction by Maricel Apuli involved the sale of 2,000 shares of BridgeBio Pharma (BBIO) Common Stock. The sale was executed at $80.06 per share on July 30, 2026, under a Rule 10b5-1 trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Apuli Maricel

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/30/2026		S⁽¹⁾		2,000	D	$80.06	127,401	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.

Remarks:

	/s/ Maricel Apuli	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR